The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific mutations making it to market.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh